newsletter masthead
November 30, 2018
Sossey-Alaoui Awarded Nearly $2M from NCI for Triple Negative Breast Cancer Investigation
Cleveland Clinic researcher  Khalid Sossey-Alaoui, Khalid Sossey-Alaoui PhD PhD , will investigate pathways that allow triple negative breast cancer (TNBC) to develop and spread with new funding from the National Cancer Institute.

The grant will bring Dr. Sossey-Alaoui and his team closer to a treatment that will either inhibit expression of the WAVE3 protein or prevent WAVE3 from binding with YB1. His team's earlier work displayed that levels of WAVE3 were elevated in TNBC and that the spread of cancerous cells was reduced when the protein was "silenced." The discovery is impactful as triple negative breast cancer cells do not respond well to treatment, making the the cancer especially lethal.

Dr. Sossey-Alaoui is a member of the Molecular Oncology Program of the Case CCC. more>
Recipient of 2018 Linda K. Arena Scholarship for Lung Cancer Education Announced
Earlier this year, applications were sought for a $6,500 scholarship designated toward lung cancer education and research in all aspects of lung cancer that may directly impact patient care.

University Hospitals Seidman Cancer Center has announced that Pranjal Vaidya, MSc was selected to receive the commemorative award for "Pre-treatment radiomic features can differentiate hyperprogression from other response patterns following immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)."

The endowed scholarship award was created by Natalie Parke, Jennifer Krahe and Stefanie Arena after their mother Linda Arena, an otherwise healthy and active non-smoker, was diagnosed with lung cancer and succumbed to the disease. 
Updates on the Cancer Moonshot from Dr. Dinah Singer
By identifying opportunities to accelerate progress in Cancer Moonshot Logo cancer research, encourage greater collaboration and improve the sharing of data, the National Cancer Institute (NCI) developed 12 initiatives to fund goals from their Blue Ribbon Panel (BRP) report.

The 21st Century Cures Act, supported by Congress, authorizes $1.8 billion of Cancer Moonshot funding over 7 years. $1 billion of that amount has been appropriated to the NCI to date. In a recent blog, Dr. Dinah Singer, NCI's acting deputy director and co-chair for the Cancer Moonshot Blue Ribbon Panel, provides updates on many of the activities underway and shares key highlights on the initiatives currently being funded.

Many deadlines for 2019 funding opportunities are fast approaching. Additional funding opportunity announcements will continue to be published.
Cancer Center Seminar Series: "Discovery and characterization of cell active inhibitors of Lactate Dehydrogenase (LDH) using structure-based design"
Nov 30, 12p | WRB Auditorium

Alex Waterson PhD Join us Friday, November 30 at 12p in the WRB Auditorium to hear Alex G. Waterson, PhD  present "Discovery and characterization of cell active inhibitors of Lactate Dehydrogenase (LDH) using structure-based design. Dr. Waterson is director and scientific coordinator at the Vanderbilt Center for Cancer Drug Discovery and research associate professor of pharmacology and chemistry at Vanderbilt University.

A synthetic organic chemist by training, Dr. Alex Waterson joined GlaxoSmithKline as a medicinal  chemist in 2001, contributing to covalently modifying ErbB inhibitors and the B-Raf drug  Dabrafenib. On moving to Vanderbilt in 2008, he helped establish a Vanderbilt center in the  National Cancer Institute (NCI) Chemical Biology Consortium (CBC) and joined Professor Fesik's  fragment-based group. There, he has led primarily oncology drug discovery projects aimed at  direct and indirect inhibition of K-Ras, as well as protease, epigenetic, and cancer metabolism  targets.   more>
American Society of Hematology 60th Annual Meeting & Exposition
December 1-4, 2018 | San Diego, CA

ASH logo The American Society of Hematology will host its 60th Annual Meeting & Exposition the first weekend of December, 2018.

View chairs, presenters and papers from Cleveland-based institutions here.
San Antonio Breast Cancer Symposium
December 4-8, 2018 | San Antonio, TX

san antonio breast cancer symposium The 2018 San Antonio Breast Cancer Symposium is taking place during the first week of December. 
The symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease to an international audience of academic and private physicians and researchers.

View spotlight session and posters featuring Cleveland-based institutions here.
3rd Annual Cancer Disparities Symposium
Mar 1, 2019 | Tinkham Veale University Center
Disparities Banner 2019-final
The 3rd Annual Cancer Disparities Symposium will be held Friday, Mar 1, 2019. 


Registration is now OPEN for this symposium.  
Click here for registration information.

2019 Symposium Highlights
  • Eliseo J. Pérez-Stable, MD, Director, National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), will discuss cancer disparities research trends and funding opportunities. 
  • Rick Kittles, PhD, Associate Director of Health Equities at City of Hope, will give a research-focused presentation on cancer disparities research. 
  • An entire afternoon session is devoted to research aligned with abstract submissions; this includes oral presentations from selected abstracts, plus a poster session. Students who submit an abstract can attend this symposium free of charge. 
  • The audience for this symposium is diverse in background and field, allowing attendees to interact, network, and expand their knowledge and opportunities for collaboration.
Call for Abstracts

The Case Comprehensive Cancer Center invites multidisciplinary researchers, community agencies and organizations to submit abstracts for presentation at the 3rd Annual Cancer Disparities Symposium. Abstracts will be divided into two tracks: Scientific Research and Community Programs. Meritorious abstracts will be selected for oral presentations. 

**Students who submit an abstract are able to register for FREE! Submit your abstract to   BEFORE  registering. You will be emailed a discount code to be entered on the registration form so that you receive the discount. 


Abstracts must be submitted via email ( ) by 5pm EST on December 21, 2018.
Crain's Cleveland - Nov 15, 2018
"This collaborative community health assessment represents a new way of working together as we highlight a shared vision of improved health for our community," said Heidi Gullett, MD, MPH. Dr. Gullett, member of the Case CCC, co-chaired the 2018 health assessment steering committee.

When Doctors Become Caregivers
AARP - Nov 23, 2018
Cleveland Clinic hematologist and oncologist  Mikkael A. Sekeres, MD, MS, member Case CCC, shares his experience and lessons learned from becoming a caregiver when his mother was diagnosed with lung cancer last year.

Fox 8 News - Nov 27, 2018
Cleveland Clinic's Dale R. Shepard, MD, PhD touches on how with use ofthe new drug, Larotrectinib, all tumors with a specific mutation gene called TRK, can be treated the same way. That includes 17 different malignancies, mostly rare cancers, but also a small portion of salivary gland tumors, lung and breast cancers, said Shepard, member of the Case CCC.
NIH BULLETIN - Notices and Funding Opportunities
Notice of Fiscal Policies in Effect for FY 2019

Request for Applications
Program Announcements
Fri, Nov 30
Cancer Center Seminar Series Guest Speaker
Alex G. Waterson, PhD Director, Scientific Coordinator, Vanderbilt Center for Cancer Drug Discovery Research Associate Professor, Pharmacology Research Associate Professor, Chemistry 
Vanderbilt University
"Discovery and characterization of cell active inhibitors of Lactate Dehydrogenase (LDH) using structure-based design"
12p WRB Auditorium
Mon, Dec 3
Tumor Immunology and Immunotherapy Meeting:  Defne Batik Watson
4p WRB 1422D
Tues, Dec 4
Cancer Center Research in Progress Seminar
3p WRB 3136
Thurs, Dec 6
Developmental Therapeutics Journal Club
9a R4-013

Molecular Biology and Microbiology Seminar
Marie McCausland and Braulio Llorens
Levine lab, CWRU
1p SOM W203

Prostate Cancer Working Group Seminar Series & Journal Club
Michael Haffner, MD, PhD
Clinical Fellow Genitourinary Pathology, The Johns Hopkins University School of Medicine
"A translational pathology approach to prostate cancer"
3p NE1-205
Fri, Dec 7
Taussig Cancer Institute Grand Rounds
8a CA5-120

Cancer Center Seminar Series
Mohamed Abazeed, MD, PhD
Director, Center for Precision Radiotherapy
Department of Radiation Oncology
Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine
"On prediction in complex systems"
12p WRB Auditorium
Mon, Dec 10
Shared Resources Directors Meeting
12p WRB 1422D

Genomic Medicine Institute Trainee Distinguished Speaker
Mien-Chie Hung, PhD
Vice President for Basic Research
Professor and Chair
University of Texas MD Anderson Cancer Center
"Marker-guided target therapy, PARP and EGFR inhibitors, and development of effective checkpoint therapy"
12p NE1-205
Tues, Dec 11
Radiation Oncology Grand Rounds
Javier Torres-Roca, MD
Director of Research,  Associate Professor and Radiation Oncologist, Department of Radiation Oncology, Moffitt Cancer Center
"Precision Medicine in Radiation Oncology"
8:10a Kulas Auditorium

Cancer Impact Lecture
Randal Kimple, MD, PhD
Associate Professor, Human Oncology, University of Wisconsin
1p NE1-205

Cancer Research in Progress Seminar
3p WRB 3136
Weds, Dec 12
Case CCC Holiday Party
5-8p Glidden House
Thurs, Dec 13
Developmental Therapeutics Journal Club
9a R4-013

Molecular Biology and Microbiology Seminar
Mary Ann Checkley and Benjamin Luttge
Karn lab, CWRU
1p SOM W203
Fri, Dec 14
Taussig Cancer Institute Grand Rounds
8a CA5-120

Cancer Center Seminar Series Guest Speaker
Eben Rosenthal, MD Associate Director of Clinical Care, Stanford Cancer Institute
Medical Director, Stanford Cancer Center
"Enhanced surgical margin detection - 'Light up my tumor' "
12p WRB Auditorium

Deadline: Open

Deadline: Open

Deadline: Open
Case Comprehensive Cancer Center